3 completed, 3 recruiting, 1 not yet recruiting, 1 terminated. 9 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Minimal Change Disease: new trials by email Literature Review of Minimal Change Disease trials Research Report on Minimal Change Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases WAL0921, Placebo - Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis | Phase 2 | Recruiting | Walden Biosciences | 96 | 2024-07-02 | 2026-08-03 |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease adalimumab - FSGS, MCD | Phase 2 | Completed | University of Michigan | 7 | 2019-10-02 | 2024-10-30 |
| Valproic Acid for Idiopathic Nephrotic Syndrome Valproic Acid - Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 / Phase 3 | Unknown | Universitair Ziekenhuis Brussel | 15 | 2016-10-01 | 2017-06-20 |
| Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) Abatacept, Normal Saline, D5W - Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Bristol-Myers Squibb | 36 | 2016-03-09 | 2021-03-05 |
| Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome Tacrolimus - Minimal Change Disease | Phase 2 / Phase 3 | Completed | Seoul National University Hospital | 20 | 2010-06-01 | 2011-08-16 |
Nephrosis, Lipoid (9) · Glomerulosclerosis, Focal Segmental (7) · Macular dystrophy, corneal type 1 (3) · Glomerulonephritis, IGA (2) · Kidney Diseases (2) · Nephrotic Syndrome (2) · Diabetic Nephropathies (1) · Glomerulonephritis, Membranous (1) · IgA Vasculitis (1) · Nephritis, Hereditary (1) · Proteinuria (1)
Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Nephrosis (9) · Urogenital Diseases (9) · Urologic Diseases (9) · Glomerulonephritis (8) · Nephritis (8) · Kidney Diseases (7) · Autoimmune Diseases (3) · Immune System Diseases (3) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Blood Coagulation Disorders (1) · Cardiovascular Diseases (1)
Abatacept (1) · Adalimumab (1) · Glucose (1) · N-acetylmannosamine (1) · Saline Solution (1) · Tacrolimus (1) · Valproic Acid (1) · Water (1) · sparsentan (1)
Bristol-Myers Squibb (1) · National Human Genome Research Institute (NHGRI) (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Seoul National University Hospital (1) · Tenet Medicines (1) · Travere Therapeutics, Inc. (1) · Universitair Ziekenhuis Brussel (1) · University of Michigan (1) · Walden Biosciences (1)
United States (6) · South Korea (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Germany (1) · India (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Poland (1) · Spain (1) · Sri Lanka (1) · Sweden (1)
Peter Janssens, MD (1) · Radko Komers, MD, PhD (1) · Rekha Abichandani, MD (1) · William A Gahl, M.D. (1) · Zubin Modi, MD (1)
PMID 38724717, PMID 35224732, PMID 35230699, PMID 39808779, PMID 40337980, PMID 40938675, PMID 41630898, PMID 42384439
2015 (1)